Cervical Insufficiency: Diagnosis, Cerclage, Progesterone, and Pessary in Preterm Birth Prevention
Executive Summary
Cervical insufficiency is the inability of the uterine cervix to retain a pregnancy in the second trimester in the absence of contractions or labor. Diagnosis rests on (1) history of ≥3 painless second-trimester losses with cervical dilation in the absence of bleeding/contractions/abruption; (2) transvaginal ultrasound demonstrating short cervical length <25 mm before 24 weeks in singleton with prior preterm birth, and (3) physical examination showing painless dilation in the second trimester. Three cerclage indications — history-indicated (12–14 weeks), ultrasound-indicated (16–23+6 weeks for cervical length <25 mm with prior spontaneous preterm birth <34 weeks), and physical-exam-indicated (rescue, up to 23+6 weeks). Vaginal progesterone 200 mg suppository nightly reduces preterm birth in singletons with short cervix <25 mm without prior preterm birth. Arabin pessary is an option in selected centers. Combined cerclage + progesterone may benefit highest-risk patients.
1. Pathophysiology & Definition
The cervix functions as a structural barrier maintaining intrauterine contents during pregnancy. Its mechanical integrity derives from a dense extracellular matrix rich in cross-linked type I collagen, type III collagen, elastin, and proteoglycans (decorin, biglycan), with smooth muscle accounting for only ~10–15% of cervical stromal mass. Cervical remodeling through pregnancy progresses through four overlapping phases: softening (early gestation), ripening (third trimester), dilation (labor), and postpartum repair. In cervical insufficiency, the softening and ripening phases initiate prematurely — typically without painful contractions.
The pathophysiologic spectrum spans:
- True structural cervical insufficiency — congenital connective tissue defects (Ehlers-Danlos, hypermobility spectrum), in-utero diethylstilbestrol exposure (now historical), uterine anomalies, or acquired weakness from prior cervical surgery (LEEP, cold-knife conization, repeated mechanical dilation, large laceration during prior delivery).
- Inflammation-mediated premature ripening — subclinical chorioamnionitis driven by ascending genital tract infection (Ureaplasma, group B streptococcus, bacterial vaginosis–associated organisms) prematurely activates matrix metalloproteinases MMP-1, MMP-8, and MMP-9, accelerating collagen degradation and cervical funneling.
- Idiopathic / multifactorial — the majority. Likely reflects an interplay of constitutional connective tissue properties, subclinical inflammation, and progesterone receptor signaling.
The functional cervical length curve in normal pregnancy plateaus at approximately 35–40 mm through 24 weeks, then progressively shortens. A length below the 10th percentile for gestational age (≈25 mm at 22–24 weeks in singletons) defines short cervix and is a powerful predictor of spontaneous preterm birth — risk approximately 6× elevated when cervical length is <25 mm at midtrimester ultrasound.
2. Diagnostic Criteria & TVUS Surveillance
ACOG / SMFM diagnostic criteria
| Diagnostic route | Criteria | Action |
|---|---|---|
| History-indicated | ≥3 prior painless second-trimester losses (16–24 wk) with cervical dilation in the absence of contractions, abruption, or chorioamnionitis | Plan history-indicated cerclage at 12–14 wk in subsequent pregnancy |
| Ultrasound-indicated | Singleton, prior spontaneous preterm birth <34 wk, AND cervical length <25 mm before 24 wk | Offer cerclage at 16–23+6 wk + vaginal progesterone |
| Physical-exam-indicated (rescue) | Painless cervical dilation ≥1 cm on speculum or digital exam at <24 wk without preterm labor or chorioamnionitis | Consider rescue cerclage up to 23+6 wk after exclusion of infection/abruption |
| Universal short-cervix screening: ACOG recommends consideration of universal mid-trimester (18–24 wk) cervical length screening in ALL singletons during anatomy ultrasound — to identify candidates for vaginal progesterone if cervical length <25 mm. | ||
Transvaginal ultrasound technique
TVUS is the gold standard for cervical length assessment. Key technical requirements:
- Empty maternal bladder (full bladder elongates the cervix and falsely reassures).
- Patient supine, knees flexed; insert probe with minimal pressure to avoid compressing the cervix.
- Identify internal os, external os, and cervical canal in midsagittal view; the canal should appear as a thin echogenic line.
- Measure shortest length from internal os to external os along the canal (not a straight line if the canal is curved).
- Apply transfundal pressure for 15 seconds — if dynamic shortening or funneling appears, document the new length.
- Repeat 3 measurements; report the shortest reproducible value.
Funneling is dilation of the internal os with protrusion of membranes into the canal — described as T (no funnel), Y, V, or U shape (progressively wider). U-shape funneling with cervical length <15 mm carries the highest preterm birth risk.
3. Cerclage: Indications & Technique
Surgical approaches
| Procedure | Approach | Suture material | Notes |
|---|---|---|---|
| McDonald | Vaginal — purse-string at cervicovaginal junction | Mersilene 5 mm tape | Most common; technically simpler; removed at 36–37 wk |
| Shirodkar | Vaginal — submucosal placement higher on cervix after bladder advancement | Mersilene 5 mm tape | Higher placement may have slightly better outcomes; technically more demanding |
| Transabdominal cerclage | Laparotomy or laparoscopy — placed at cervicoisthmic junction | Mersilene tape | Reserved for failed transvaginal cerclage or absent vaginal cervix; requires cesarean delivery |
| Pre-conception transabdominal cerclage may be performed laparoscopically and left in situ between pregnancies — increasingly used in patients with prior failed transvaginal cerclage. | |||
Three cerclage indications
1. History-indicated (prophylactic) cerclage
Performed at 12–14 weeks in patients with classic history of recurrent painless mid-trimester loss. Pre-procedure: confirm viable singleton pregnancy, normal anatomic survey, exclude fetal anomalies, screen for and treat any vaginal infection. Anesthesia: regional (spinal) preferred over general. Removed at 36–37 weeks unless preterm labor, PPROM, or chorioamnionitis intervenes.
2. Ultrasound-indicated cerclage
Performed in patients meeting BOTH of: (a) singleton with prior spontaneous preterm birth <34 weeks, AND (b) cervical length <25 mm before 24 weeks. The MFMU Cerclage trial and Berghella meta-analyses support significant preterm-birth reduction in this population. Cerclage placement is at 16–23+6 weeks based on TVUS surveillance every 1–2 weeks. Combine with vaginal progesterone if not already initiated.
3. Physical-exam-indicated (rescue) cerclage
Indicated when speculum/digital examination at <24 weeks reveals painless cervical dilation ≥1 cm with or without visible membranes — in the absence of preterm labor, chorioamnionitis, abruption, or PPROM. Pre-procedure exclusion: amniocentesis to exclude subclinical chorioamnionitis is considered in high-risk situations (prior failed cerclage, suspicious clinical findings); WBC, glucose, gram stain, IL-6, and cultures are interpreted together. Reverse Trendelenburg position, bladder filling to push membranes upward, and rescue suture placement may achieve gestational prolongation of 7–13 weeks in observational studies.
4. Vaginal Progesterone & Pessary
Vaginal progesterone
Vaginal progesterone is recommended for singleton patients with incidentally discovered short cervix <25 mm at midtrimester TVUS without prior preterm birth. Standard regimen: 200 mg micronized progesterone vaginal suppository nightly initiated upon diagnosis through 36+6 weeks. Alternative: 90 mg progesterone gel daily.
Mechanism — progesterone maintains uterine quiescence by inhibiting prostaglandin synthesis, reducing myometrial gap junction formation, suppressing oxytocin receptor expression, and stabilizing the cervical extracellular matrix. The PREGNANT trial and meta-analyses demonstrate ~45% relative reduction in preterm birth <33 weeks in singletons with short cervix.
| Preventive intervention | Indication | Evidence |
|---|---|---|
| Vaginal progesterone 200 mg HS | Singleton + short cervix <25 mm + no prior preterm birth | Multiple RCTs + Cochrane meta-analysis support; ~45% PTB reduction |
| Cerclage + progesterone | Singleton + short cervix <25 mm + prior preterm birth <34 wk | Combined approach favored in highest-risk group |
| 17α-hydroxyprogesterone caproate (17-OHPC) IM | WITHDRAWN — Makena withdrawn from US market April 2023 after PROLONG trial failure | No longer recommended; vaginal progesterone preferred |
| Arabin pessary | Singleton, short cervix; selected centers | Conflicting RCTs; ProTWIN positive in twins, PECEP positive in singletons, OPPTIMUM/PROMISE neutral; not first-line in US |
| Bed rest, activity restriction | Historically prescribed | NO benefit; risk of VTE, deconditioning, psychosocial harm — DO NOT prescribe |
Arabin pessary
The Arabin cervical pessary is a flexible silicone cup that surrounds the cervix and theoretically redirects intrauterine pressure away from the internal os, reducing mechanical stress on the lower uterine segment. Insertion is an office procedure; no anesthesia is required. Removal at 37 weeks or with PPROM/labor onset.
Evidence remains conflicting — the original ProTWIN (Goya, twins) and PECEP (Goya, singletons) trials reported significant reductions in preterm birth, but the larger OPPTIMUM, PROMISE, and PESAPRO trials found no benefit. The 2024 ACOG Practice Bulletin notes pessary as an option but does not endorse routine use; SMFM advises against routine pessary use in singletons.
✓ Pearl
For a patient with prior spontaneous preterm birth <34 weeks who reaches 16 weeks in the next pregnancy with a normal cervical length, do NOT place prophylactic cerclage. Instead initiate vaginal progesterone and serial TVUS every 2 weeks from 16 to 24 weeks. If cervical length falls below 25 mm, place ultrasound-indicated cerclage. This avoids unnecessary surgery while maintaining vigilance.
✗ Pitfall
17-OHPC (Makena) was withdrawn from the US market in April 2023 after the PROLONG confirmatory trial failed to reproduce the original Meis 2003 finding. Do NOT prescribe. Vaginal progesterone is the only progesterone-class intervention currently supported by guidelines for preterm-birth prevention in singletons.
5. Special Populations & Complications
Special populations
| Population | Approach | Notes |
|---|---|---|
| Twin gestation, short cervix <25 mm | Vaginal progesterone (200 mg HS) is reasonable; cerclage controversial | Routine cerclage NOT indicated; selective cerclage for cervix <15 mm may benefit |
| Twin gestation, prior preterm birth | Vaginal progesterone; cerclage individualized | Less clear benefit than singletons |
| Acute cervical insufficiency >23+6 wk | NO cerclage; tocolysis, antenatal corticosteroids, magnesium for neuroprotection if 24–32 wk | Risk-benefit shifts toward conservative management |
| Prior LEEP / cone biopsy | TVUS surveillance every 2 weeks from 16–24 weeks; ultrasound-indicated cerclage if <25 mm | Risk increases with cone depth >15 mm and repeated procedures |
| Mullerian anomalies (unicornuate, septate) | Higher baseline preterm birth risk; TVUS surveillance | Cerclage benefit uncertain; individualize |
| PPROM at 16–24 weeks | Cerclage in situ → typically removed; expectant management of PPROM | Leaving cerclage in place increases chorioamnionitis risk |
Complications of cerclage
- Chorioamnionitis — 1–9%; higher in physical-exam-indicated rescue cerclage (10–30%).
- PPROM — 1–18% across indication groups; higher in rescue cerclage.
- Preterm labor / contraction induction — typically transient; managed expectantly or with tocolysis.
- Cervical laceration — at delivery if cerclage is not removed in time, especially if labor onset is rapid.
- Bladder injury, hemorrhage, suture displacement — uncommon.
- Cervical stenosis or dystocia — rare with timely removal.
Cerclage removal
Plan removal at 36+0 to 37+0 weeks. Earlier removal indicated for: preterm labor unresponsive to tocolysis, PPROM, chorioamnionitis, severe vaginal bleeding, or non-reassuring fetal status. McDonald cerclage removal is typically performed in clinic without anesthesia; Shirodkar may require regional anesthesia. Transabdominal cerclage is left in place permanently and the patient is delivered by cesarean — between pregnancies the cerclage remains.
6. Frequently Asked Questions
Should every pregnancy receive universal mid-trimester cervical length screening?
Is a history-indicated cerclage always required after one prior second-trimester loss?
What is the upper gestational age limit for placing cerclage?
Should we still use 17-hydroxyprogesterone caproate (17-OHPC, Makena)?
Can a transabdominal cerclage be placed before pregnancy?
S7. Practice Insights: Cervical Insufficiency Three-Indication Algorithm
1. Three Cerclage Indication Categories
In practice, every cerclage decision begins with categorizing the patient into one of three established indications. History-indicated cerclage (formerly “elective”): patient with 3+ prior second-trimester pregnancy losses or preterm births in the setting of painless cervical dilation, with cerclage placed prophylactically at 13-14 weeks gestation. Ultrasound-indicated cerclage: patient with prior spontaneous preterm birth before 34 weeks plus current pregnancy with cervical length less than 25 mm before 24 weeks, with cerclage placed when short cervix is identified. Exam-indicated (rescue) cerclage: patient with cervical dilation 1-4 cm and visible membranes at 16-24 weeks gestation regardless of prior history. The category dictates timing and technique, and miscategorization is the dominant decision error.
2. TVUS Cervical Length Surveillance
In experienced hands, transvaginal cervical length measurement every 1-2 weeks between 16 and 24 weeks gestation is mandatory in high-risk patients: prior spontaneous preterm birth before 34 weeks, history of cervical surgery (LEEP, cone biopsy), Mullerian anomaly, multiple gestation in some protocols. Normal cervical length is ≥30 mm. Surveillance threshold for intervention: less than 25 mm before 24 weeks triggers consideration of cerclage or progesterone based on the indication category. Less than 10 mm warrants rescue cerclage consideration regardless of prior history. The standardized technique matters — transvaginal probe with empty bladder, three measurements taken with the shortest used, proper image quality with calibration markers visible.
3. Cerclage vs Vaginal Progesterone
In practice, the choice between cerclage and vaginal progesterone is driven by patient profile. Vaginal progesterone (200 mg suppository nightly) is appropriate for: singleton pregnancy WITHOUT prior preterm birth but with incidentally discovered short cervix less than 25 mm at 16-24 weeks. Cerclage (typically McDonald technique transvaginally) is appropriate for: singleton with prior spontaneous preterm birth less than 34 weeks AND current short cervix less than 25 mm; or the three-indication categories above. Combined cerclage plus progesterone may be considered in select high-risk patients but standard practice is either-or. Both approaches reduce preterm birth approximately 30-40% in appropriate populations.
4. Twin Gestation: Mixed Evidence
Twin gestations are a more difficult management space. Multiple studies have not consistently shown benefit from prophylactic cerclage in twin pregnancies with short cervix, and some early studies showed potential harm. In experienced practice, experienced clinicians now recommend: ultrasound-indicated cerclage in twins with cervical length less than 15 mm at less than 24 weeks (small subgroup analysis suggests benefit at this severe threshold); no routine cerclage for twins with cervical length 15-25 mm without other indications; vaginal progesterone has limited evidence in twins but is often used; pessary has had mixed trial results with some European data supporting use but US guidance has been more skeptical. clinicians document the shared decision-making with the patient about uncertainty in twin pregnancy management.
Illustrative Scenario: Ultrasound-Indicated Cerclage After Prior Preterm Birth
A woman in her early 30s G2P1 with prior spontaneous preterm birth at 28 weeks (her first pregnancy 2 years ago resulted in a NICU graduate now doing well) was followed at 16, 18, and 20 weeks with TVUS cervical length measurements. At 20 weeks, cervical length was 21 mm (down from 32 mm at 16 weeks), with normal placentation, no contractions, normal urinalysis.
She met ultrasound-indicated cerclage criteria. After shared decision-making about benefits/risks (~30-40% preterm birth reduction vs procedural risks of bleeding, infection, membrane rupture ~1%), she elected to proceed with McDonald cerclage placement at 20+4 weeks. Procedure was uncomplicated. She continued progesterone given the prior preterm history (combined approach in this high-risk subgroup). Cerclage was removed at 37+0 weeks. She delivered vaginally at 38+2 weeks, full-term healthy infant. Without intervention her prior trajectory predicted a 28-30 week recurrence; the gain of 10+ weeks of gestation transformed neonatal outcomes for this family.
Practice Pattern Refinements vs Standard Approach
- Three cerclage indication categories: history (3+ losses, place 13-14 wk), ultrasound (prior preterm + CL<25mm, place when found), exam (rescue, dilation 1-4 cm 16-24 wk).
- TVUS cervical length q1-2wk between 16-24 wk in high-risk patients (prior preterm, cervical surgery, Mullerian anomaly). <25 mm intervention threshold; <10 mm rescue.
- Vaginal progesterone vs cerclage: progesterone for singleton no-prior-preterm with short cervix; cerclage for prior-preterm with short cervix. Combined for select high-risk.
- Twin gestation: cerclage only at CL <15 mm; routine cerclage 15-25 mm not supported. Progesterone limited evidence; pessary mixed.
- Premature Ovarian Insufficiency: FSH Diagnosis, Hormone Replacement
- Cervical Dysplasia (LSIL and HSIL): Pap, HPV, Colposcopy, and ASCCP-Aligned Management
- Pap Smear Interpretation: Bethesda 2014 and ASCCP 2019
- HPV Vaccination in the OB/GYN Clinic: Schedule, Efficacy, and Catch-Up Strategy
- Infertility Evaluation: ASRM/AUA Workup, Semen Analysis, and Treatment Cascade
- Twin-to-Twin Transfusion Syndrome: Quintero Staging, Fetoscopic Laser, and Surveillance